Video

Dr. O'Regan on the Status of Biosimilars in Oncology

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

Biosimilars are beginning to take off in the field of oncology, explains O’Regan. Data on trastuzumab (Herceptin) biosimilars have been presented from randomized studies, demonstrating similar safety and immunogenicity profiles. Though these biosimilars may be ready for use in practice, says O’Regan, patients who have been on trastuzumab for years may not be comfortable making the switch to the biosimilar.

Nonetheless, biosimilars are an exciting breakthrough in oncology, and there are those in development outside of breast cancer, including those that physicians use as supportive agents, notes O’Regan. Additionally, different methods of administration are being explored, such as a subcutaneous injection. There is no doubt that biosimilars will have an impact on the field of oncology, says O’Regan, but the hope is that they will ultimately decrease the cost of cancer therapy.

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA